These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21968316)

  • 21. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab for the treatment of rheumatoid arthritis.
    Tanaka T; Ogata A; Narazaki M
    Expert Rev Clin Immunol; 2010 Nov; 6(6):843-54. PubMed ID: 20979549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
    Kubandova Z; Mathieu S; Pourtier C; Soubrier M
    Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.
    Ikonomidis I; Pavlidis G; Katsimbri P; Andreadou I; Triantafyllidi H; Tsoumani M; Varoudi M; Vlastos D; Makavos G; Kostelli G; Βenas D; Lekakis J; Parissis J; Boumpas D; Alexopoulos D; Iliodromitis E
    Clin Res Cardiol; 2019 Oct; 108(10):1093-1101. PubMed ID: 30859382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.
    Benucci M; Manfredi M; Saviola G; Sarzi-Puttini P; Atzeni F
    Clin Exp Rheumatol; 2013; 31(2):322-3. PubMed ID: 23380047
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.
    Sandoo A; Panoulas VF; Toms TE; Smith JP; Stavropoulos-Kalinoglou A; Metsios GS; Gasparyan AY; Carroll D; Veldhuijzen van Zanten JJ; Kitas GD
    J Hum Hypertens; 2011 Nov; 25(11):699-702. PubMed ID: 21525886
    [No Abstract]   [Full Text] [Related]  

  • 30. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.
    Sidiropoulos PI; Siakka P; Pagonidis K; Raptopoulou A; Kritikos H; Tsetis D; Boumpas DT
    Scand J Rheumatol; 2009; 38(1):6-10. PubMed ID: 18991190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
    Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
    Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis.
    Wållberg-Jonsson S; Caidahl K; Klintland N; Nyberg G; Rantapää-Dahlqvist S
    Scand J Rheumatol; 2008; 37(1):1-5. PubMed ID: 18189187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
    Clarivet B; Robin P; Pers YM; Ferreira R; Lebrun J; Jorgensen C; Hillaire-Buys D; Brés V; Faillie JL
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1413-1414. PubMed ID: 27457374
    [No Abstract]   [Full Text] [Related]  

  • 39. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
    Miyagawa I; Nakayamada S; Saito K; Hanami K; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Mod Rheumatol; 2014 May; 24(3):405-9. PubMed ID: 24252016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.